Genisphere
- Company typePrivate
- Founded1997
- HeadquartersHatfield, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Genisphere firmographics
Firmographics- Name
- Genisphere
- Website
- https://genisphere.com
- Company type
- Private
- Founded year
- 1997
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Where Genisphere is headquartered
LocationHeadquarters
- HQ city
- Hatfield
- HQ country
- United States
- HQ region
- North America
Markets served
Genisphere business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
Genisphere product offering
Product offeringCore offering
Genisphere is a nanotechnology company that develops and operates in the nanoscale technology space. Founded in 1997 and headquartered in Hatfield, Pennsylvania, the company maintains a small team focused on nanotechnology applications. Specific product/service details are not provided in the source data.
Differentiator
Problem solved
Functional benefit
Companies that use Genisphere
Customer profileIdeal customer profiles1 record
Genisphere technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Genisphere partnerships and signals
Strategic signalRecent moves2 records
Expansion highlights1 record
Genisphere competitors and assessment
Company assessmentBroad incumbents
- Moderna: Commercial-stage mRNA therapeutics and vaccines company that depends heavily on lipid nanoparticle delivery technology. Adjacent incumbent whose success in LNP delivery validates the broader nanocarrier thesis relevant to Genisphere's platform.
- Alnylam Pharmaceuticals: Leading commercial-stage RNAi therapeutics company with multiple approved products and a deep pipeline. Broad incumbent in the same nucleic-acid delivery space where Genisphere operates, though orders of magnitude larger and commercially proven.
- Nanobiotix: Late-stage clinical nanomedicine company developing first-in-class nanoparticle-based oncology products. Broader incumbent peer in nanomedicine with regulatory-stage assets, providing a market validation reference for Genisphere's platform thesis.
- BioNTech: Commercial-stage immunotherapy company using nanoparticle-formulated mRNA for cancer and infectious disease. Broad incumbent in nucleic-acid delivery that competes for the same pharma partnering dollars that Genisphere's 3DNA platform could pursue.
Direct peers
- BIND Therapeutics: Was a clinical-stage nanomedicine company developing targeted polymeric nanoparticle therapeutics for cancer. Direct peer to Genisphere in the nanoparticle/nanotech drug delivery space, working on similar platform-based targeted delivery approaches.
- Selecta Biosciences: Clinical-stage biotech developing synthetic nanoparticle immunotherapies and tolerogenic treatments using a proprietary nanocarrier platform. Direct peer to Genisphere in leveraging nanoparticle platforms for therapeutic delivery.
- Aura Biosciences: Clinical-stage oncology company developing virus-like particle drug conjugates for targeted tumor therapy. Comparable to Genisphere as a small, platform-based nanobiotech pursuing targeted therapeutic delivery.
- Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics company using targeted nanoparticle delivery systems. Comparable to Genisphere in developing nucleic-acid-based therapeutics that depend on proprietary nanocarrier technology for in vivo delivery.
- Cerulean Pharma: Was a clinical-stage nanopharmaceutical company developing nanoparticle-drug conjugates for cancer. Closely comparable to Genisphere in platform-based nanocarrier drug delivery before being acquired.
- Nanospectra Biosciences: Clinical-stage company developing tunable nanoparticle therapeutics, notably AuroLase for thermal ablation of solid tumors. Closely comparable to Genisphere as a small-cap nanomedicine platform developing targeted nanoscale interventions.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks6 records
Key highlights5 records
Customer concentration
Genisphere social profiles
Digital presenceGenisphere financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genisphere leadership team
Management profileNumber of profiles
Profiles2 records
Genisphere funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genisphere M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genisphere
What does Genisphere do?
Genisphere is a nanotechnology company that develops and operates in the nanoscale technology space. Founded in 1997 and headquartered in Hatfield, Pennsylvania, the company maintains a small team focused on nanotechnology applications. Specific product/service details are not provided in the source data.
When was Genisphere founded?
Genisphere was founded in 1997. It employs 11 to 50 people.
Where is Genisphere based?
Genisphere is headquartered in Hatfield, United States, in the North America region.
Who are Genisphere's main competitors?
Broad incumbents on record are Moderna, Alnylam Pharmaceuticals, Nanobiotix and BioNTech. Direct peers are BIND Therapeutics, Selecta Biosciences, Aura Biosciences, Arrowhead Pharmaceuticals, Cerulean Pharma and Nanospectra Biosciences.
Does Genisphere have an API?
No public API is recorded for Genisphere.